Retrospective clinical study on Bielong Ruangan Tablets combined with antiviral drugs in treating hepatitis B cirrhosis
Objective To explore the clinical efficacy and safety of Bielong Ruangan Tablets(BLRGT)combined with antiviral drugs in treating hepatitis B cirrhosis.Methods A retrospective clinical study was conducted to collect the clinical data of patients diagnosed with hepatitis B cirrhosis in the Department of Hepatology of the First Hospital of Hunan University of Chinese Medicine from January 1,2014 to December 31,2016.A total of 216 cases in the pre-matching treatment group and 78 cases in the pre-matching control group were included.Based on the baseline data,propensity score matching(PSM)was carried out between the two groups,resulting in 69 cases in both of the treatment and control groups.After PSM,the one-,three-,and five-year survival rates and survival time,and the incidence and required time of clinical endpoint events of cirrhosis within five years in the two groups of patients were observed to evaluate the efficacy;the total incidence of upper gastrointestinal bleeding and the incidence of it in different levels of platelet(PLT)count,as well as other adverse reactions in the two groups of patients were observed to evaluate the safety.Results(1)The one-,three-,and five-year overall survival rates were 97%,77%,and 68%in the treatment group,and 91%,57%,and 52%in the control group,respectively.The average survival time of the treatment group was longer than that of the control group(P<0.05).(2)The average time required for the occurrence of clinical endpoint events of cirrhosis in the treatment group was longer than that in the control group(P<0.05);the incidence of ascites was lower in the treatment group than that in the control group(P<0.05);(3)After PSM,there was no statistically significant difference in the total incidence of upper gastrointestinal bleeding between the two groups(P＞0.05).Besides,the patients in each group were divided into levels of PLT<30×109/L,30×109/L≤PLT<50×109/L,50×109/L≤PLT<100×109/L,and PLT≥100×109/L according to the PLT count.The incidence of upper gastrointestinal bleeding at all levels was no statistically significant difference(P＞0.05).(4)Some patients who have taken BLRGT may experience discomfort in the epigastrium,diarrhea,abdominal distension,and other adverse reactions.The severity is mild,and it can be relieved on its own.Conclusion BLRGT can improve the survival rate of patients with hepatitis B cirrhosis,reduce the incidence of ascites in cirrhosis,delay the occurrence of endpoint events in cirrhosis,and have a solid long-term efficacy,and sound clinical safety,without increasing the risk of upper gastrointestinal bleeding.
Bielong Ruangan Tabletshepatitis B cirrhosisclinical endpoint event in cirrhosissurvival ratepropensity score matching
万方数据
维普
